应对心血管影像未满足临床需求的放射性示踪剂,第2部分:炎症、纤维化、血栓形成、钙化与淀粉样变影像
本综述第2部分讨论用于心血管炎症、血栓形成、纤维化、钙化和淀粉样变影像的PET与SPECT放射性示踪剂;这些示踪剂可能有助于动脉粥样硬化斑块风险分层、血栓检测以及心肌病的诊断、表征和风险分层。文中涉及靶向炎症反应各环节、纤维蛋白(如64Cu标记的纤维蛋白结合探针8)、成纤维细胞激活蛋白(如68Ga-成纤维细胞激活蛋白抑制剂)、18F-NaF及99mTc-焦磷酸盐和18F-氟倍他吡等示踪剂。
要点
- 综述讨论靶向炎症、血栓、纤维化、钙化和淀粉样变的心血管PET/SPECT示踪剂。
- 这些示踪剂可能用于动脉粥样硬化斑块风险分层、血栓检测及心肌病诊断与风险分层。
- 涉及的示踪剂包括64Cu标记纤维蛋白结合探针8、68Ga-FAPI、18F-NaF、99mTc-焦磷酸盐和18F-氟倍他吡。
核心结论
- 这些放射性示踪剂可能有助于解决动脉粥样硬化斑块风险分层、血栓检测以及心肌病诊断、表征和风险分层等未满足需求。
研究设计与样本
- 本文为两部分综述的第2部分,讨论选定的用于心血管炎症、血栓形成、纤维化、钙化和淀粉样变影像的PET与SPECT放射性示踪剂。
主要发现
- 炎症部分讨论靶向心肌梗死、心肌炎、结节病、动脉粥样硬化和血管炎等病理中炎症反应各环节的示踪剂。
- 血栓部分讨论检测全身性和器械相关血栓的示踪剂,如靶向纤维蛋白的64Cu标记纤维蛋白结合探针8。
- 纤维化部分讨论靶向成纤维细胞激活蛋白的新兴示踪剂,如68Ga-成纤维细胞激活蛋白抑制剂。
- 钙化与淀粉样变部分简要回顾18F-NaF以及99mTc-焦磷酸盐和18F-氟倍他吡等示踪剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiovascular imaging is evolving in response to systemwide trends toward molecular characterization and personalized therapies. The development of new radiotracers for PET and SPECT imaging is central to addressing the numerous unmet diagnostic needs that relate to these changes. In this 2-part review, we discuss select radiotracers that may help address key unmet clinical diagnostic needs in cardiovascular medicine. Part 1 examined key technical considerations pertaining to cardiovascular radiotracer development and reviewed emerging radiotracers for perfusion and neuronal imaging. Part 2 covers radiotracers for imaging cardiovascular inflammation, thrombosis, fibrosis, calcification, and amyloidosis. These radiotracers have the potential to address several unmet needs related to the risk stratification of atheroma, detection of thrombi, and the diagnosis, characterization, and risk stratification of cardiomyopathies. In the first section, we discuss radiotracers targeting various aspects of inflammatory responses in pathologies such as myocardial infarction, myocarditis, sarcoidosis, atherosclerosis, and vasculitis. In a subsequent section, we discuss radiotracers for the detection of systemic and device-related thrombi, such as those targeting fibrin (e.g., 64Cu-labeled fibrin-binding probe 8). We also cover emerging radiotracers for the imaging of cardiovascular fibrosis, such as those targeting fibroblast activation protein (e.g., 68Ga-fibroblast activation protein inhibitor). Lastly, we briefly review radiotracers for imaging of cardiovascular calcification (18F-NaF) and amyloidosis (e.g., 99mTc-pyrophosphate and 18F-florbetapir).
引用
- Stendahl JC, Kwan JM, Pucar D, et al. Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging. J Nucl Med. 2022. PMID: 35772956. doi:10.2967/jnumed.121.263507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。